

SUPPLEMENTARY MATERIAL

Table E1: Baseline characteristics, treatment variables and infarct core volumes of the entire patient sample and patients with vs. without ghost core (defined as baseline CTP volume minus follow-up infarct volume > 10 ml).

Variable	All included patients (n=421)	Patients with ghost core (n=47)	Patients without ghost core (n=374)	P-value*
Age in years–median (IQR)	69.8 (60.4 – 79.7), n = 421	64.5 (53.3 – 72.6), n = 47	70.7 (61.0 – 80.4), n = 374	0.001
Female sex–n (%)	209 (49.6)	15/47 (31.9)	194/374 (51.9)	0.013
Baseline NIHSS–median (IQR)	17 (13 – 21), n = 421	17 (14 – 21), n = 47	17 (12 – 21), n = 374	0.408
Past medical history – n (%)				
Diabetes mellitus	80/421 (19.0)	6/47 (12.8)	74/374 (19.8)	0.125
Chronic renal failure	28/421 (6.7)	1/47 (2.1)	27/374 (7.2)	0.345
Past stroke or TIA	61/421 (14.5)	4/47 (11.2)	57/374 (15.2)	0.275
Coronary artery disease/ischemic heart disease	101/421 (24.0)	7/47 (14.9)	94/374 (25.1)	0.148
Congestive heart failure	53/421 (12.6)	4/47 (8.5)	49/374 (13.1)	0.487
Atrial fibrillation	128/421 (30.4)	9/47 (19.2)	119/374 (31.8)	0.092
Current smoker	81/420 (19.3)	9/47 (19.2)	72/373 (19.3)	0.816
Baseline ASPECTS–median (IQR)	8 (7 – 9), n = 421	8 (7 – 9), n = 47	8 (7 – 9), n = 374	0.462
Collaterals–n (%)				0.017
Poor	13/415 (3.1)	5/47 (10.6)	8/368 (2.2)	
Intermediate	341/415 (82.2)	37/47 (78.7)	304/368 (82.6)	
Good	61/415 (14.7)	5/47 (10.6)	56/368 (15.2)	
Occlusion site–n (%)				0.688
M1-segment	345/420 (82.1)	40/47 (85.1)	305/373 (81.8)	
ICA-Terminus	75/420 (17.9)	7/47 (14.9)	68/373 (18.2)	
eTICI 2b–3–n (%)	358/418 (85.7)	46/47 (97.9)	312/371 (84.1)	0.007
eTICI 2c–3–n (%)	189/418 (45.2)	26/47 (55.3)	163/371 (43.9)	0.162

Last known well-to-CT (min)– median (IQR)	160 (86 – 320), n = 421	91 (61 – 223), n = 47	171 (89 – 330), n = 374	0.001
CT-to-reperfusion (min– median (IQR)	77 (59 - 99), n = 380	70 (50 – 90), n = 46	77 (60 - 100), n = 334	0.053
Onset-to-randomization >6 hours – n (%)	109 (26.0)	8/47 (17.0)	101/373 (27.1)	0.160
General anesthesia–n (%)	52/418 (12.4)	3/47 (6.4)	49/371 (13.2)	0.108
Intravenous alteplase–n (%)	238/421 (56.5)	31/47 (66.0)	2017/374 (55.4)	0.212
Intravenous nerinetide–n (%)	202/421 (48.0)	23/47 (48.9)	179/374 (47.9)	1.000
Infarct core (CBF<30%) at baseline in ml – median (IQR)	9.9 (0 – 30.0), n = 421	44.6 (28.7 – 68.6), n = 47	7.3 (0 = 22.8), n = 374	<0.001
Infarct volume at 24h in ml – median (IQR)	30.8 (9.2 – 103.0), n = 421	8.6 (2.7 – 29.7), n = 47	34.0 (11.5 – 116.4), n = 374	<0.001

* Derived from Fisher’s exact test (categorical variables) and Wilcoxon rank sum test

(continuous variables)

Note: IQR=interquartile range, NIHSS=National Institutes of Health Stroke Scale,

ASPECTS=Alberta Stroke Program Early CT Score, CBF = cerebral blood flow,

eTICI=expanded Treatment in Cerebral Infarction Score, ICA=internal carotid artery, TIA = transient ischemic attack

Table E2: Imaging core lab members

Name	Subspecialty	Stroke imaging experience (years)	Role in the imaging core lab
Mayank Goyal	Neuroradiology (diagnostic & interventional)	24	Head of the imaging core lab Reperfusion assessment (TICI) Follow-up infarct assessment Decision in case of disagreement between two readers
Johanna Ospel	General radiology	4	Reperfusion assessment (TICI) Follow-up infarct assessment
Manish Joshi	Neuroradiology (diagnostic & interventional)	15	Baseline imaging assessment (NCCT, CTA)
Bijoy Menon	Stroke neurology	15	Baseline imaging assessment (NCCT, CTA)
Mohammed Almekhlafi	Stroke neurology	10	Reperfusion assessment (TICI)

Charlotte Zerna	Stroke neurology	6	Baseline imaging assessment (NCCT, CTA)
-----------------	------------------	---	---